Available online **www.ijpras.com**

International Journal of Pharmaceutical Research & Allied Sciences, 2025, 14(2):89-100
https://doi.org/10.51847/kzDSiy6ugm

Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

Designing Long-Acting Medicines Backward from the Clinical Target Product Profile, Dosing Experience, Real-World Adherence, and Implementation Constraints

Krzysztof Wiśniewski[1]*, Małgorzata Nowak[1], Tomasz Adamczyk[2]

[1] Department of Long-Acting Medicine Design and Target Profile, Faculty of Pharmacy, Warsaw University of Life Sciences, Warsaw, Poland.
[2] Department of Dosing Experience and Adherence Implementation, Faculty of Pharmacy, Jagiellonian University, Krakow, Poland.

***Email:** krzysztof.wisniewski@sggw.edu.pl*

ABSTRACT

Long-acting medicines are commonly differentiated by how long they maintain drug exposure or permit dosing to be deferred, yet nominal duration alone does not determine whether a product is clinically useful, acceptable, manufacturable, or implementable. This article proposes an original Clinical-Backcast Long-Acting Medicine Design Framework that begins with the clinical target product profile, intended use scenario, dosing experience, and health-system pathway before specifying pharmacokinetic, pharmacodynamic, formulation, process, and supply attributes. The framework treats duration as one constrained design variable within a broader product-fitness architecture. It distinguishes the required therapeutic-exposure window from residual pharmacokinetic persistence, connects potency and dose mass to platform capacity and administration burden, and requires explicit consideration of pain, reversibility, adverse-effect manageability, appointment adherence, persistence, staffing, procurement, storage, and supply continuity. Manufacturing and formulation translation are represented through traceable relationships among drug properties, excipient compatibility, release mechanisms, critical quality attributes, process variables, stability, and analytical methods. Proposed validation gates separate conceptual plausibility from experimental support, in-vitro performance from in-vivo prediction, product similarity from clinical equivalence, and technical feasibility from implementation readiness. Safety, exposure adequacy, critical manageability, and essential implementation feasibility are treated as proposed non-compensable conditions that cannot automatically be offset by a longer dosing interval. The framework is intended to organize multidisciplinary reasoning, expose hidden assumptions, and generate testable development propositions. It does not constitute a validated predictive model, a clinical recommendation, a regulatory standard, or a universally applicable development pathway. Product-specific computational, experimental, manufacturing, clinical, human-factors, and implementation evidence remains necessary before the proposed relationships can support consequential decisions.

Key words: *Pharmaceutical formulation, Dosage form, Excipient, Manufacturability, Stability, Bioavailability*
Received: 28 February 2025; **Revised:** 07 June 2025; **Accepted:** 07 June 2025

INTRODUCTION

Long-acting medicines are often approached through a technology-centred question: how can a molecule be retained, released, absorbed, or remain active for longer? Although scientifically necessary, this question is translationally incomplete. A clinically useful dosage form must also fit the intended population, therapeutic role, administration setting, monitoring pathway, and consequences of delayed, interrupted, or discontinued treatment.

Patient-centric development therefore requires product attributes to be linked to measurable patient and use outcomes rather than selected only because they are technically achievable [1]. For long-acting products, these links should be established before formulation optimization fixes assumptions about route, interval, volume, depot type, or release mechanism.

Long action can arise through slowly dissolving particles, biodegradable polymers, lipid or crystalline depots, implants, prodrugs, or biological persistence. These approaches differ in loading capacity, onset, release control, bioavailability, excipient exposure, process sensitivity, removability, and terminal pharmacokinetics [2]. Long-acting formulations therefore do not constitute a single pharmaceutical category with a uniform translational pathway. Similar dosing intervals may result from different combinations of dissolution, diffusion, erosion, absorption, metabolism, or pharmacodynamic persistence, each creating distinct analytical, manufacturing, safety, and clinical-management challenges.

Therapeutic duration is also embedded within a care system. Long-acting products may reduce medication-taking frequency while increasing dependence on appointments, trained personnel, inventory, administration windows, monitoring, and missed-dose or discontinuation strategies. Experience with long-acting HIV therapies shows that drug properties, formulation performance, patient selection, adherence, resistance risk, and service delivery must be considered together [3]. The translational objective is therefore not simply to prolong exposure, but to identify the duration, exposure pattern, product configuration, and implementation pathway that jointly support the intended clinical purpose.

This Original Translational Design Framework Article proposes a backward-design architecture beginning with the clinical target product profile and use scenario. It then derives requirements for dosing experience, exposure, dose feasibility, delivery platform, release mechanism, formulation, manufacturing controls, stability, and implementation. The framework traces each pharmaceutical attribute to an upstream clinical or use requirement while allowing feasibility evidence to revise the original profile. It is an original conceptual synthesis that organizes evidence-supported domains and proposes relationships, decision gates, and boundaries requiring prospective evaluation.

Why long duration alone does not define a successful long-acting medicine

Duration may refer to depot persistence, continued release, measurable systemic exposure, target occupancy, therapeutic effect, or the interval between administrations. These measures may overlap but are not interchangeable. A product may release drug for an extended period without maintaining adequate effect, or may sustain exposure after treatment should ideally be stopped. Patient experience also includes privacy, convenience, discomfort, clinic attendance, and confidence in maintaining treatment, as shown in qualitative accounts of long-acting injectable therapy [4]. Long action must therefore specify what persists, for whom, under which conditions, and with what consequences.

Preference cannot be represented by a universal ranking. Patients may value less frequent dosing while differing in their views on route, pain, adverse effects, administration setting, discretion, visit frequency, or reversibility. Discrete-choice evidence shows that preferences reflect combinations of attributes rather than dosing frequency alone [5]. The design objective should therefore be an acceptable product profile that makes population heterogeneity visible, rather than maximum duration or average preference. Stated preference must also be distinguished from initiation, persistence, appointment attendance, and routine use.

Extended intervals must further be evaluated alongside efficacy, safety, tolerability, administration reactions, discontinuation, and treatment-maintenance requirements. Longitudinal evidence for injectable cabotegravir plus rilpivirine shows that a long-acting regimen remains a complete therapeutic intervention with continuing clinical and administration-related outcomes [6]. A longer interval may be beneficial, neutral, or harmful depending on exposure variability, persistent adverse effects, missed-dose consequences, monitoring requirements, and service feasibility.

The framework therefore defines long-acting product fitness as alignment among therapeutic duration, exposure adequacy, dose and administration burden, safety manageability, patient experience, manufacturing reliability, and implementation feasibility. This is not a validated composite score. Some attributes may permit trade-offs, whereas others may represent non-compensable boundaries. An unacceptable safety tail, inadequate exposure, infeasible dose volume, or absence of essential service capacity should not be offset simply because the product lasts longer. Duration has value only when its mechanism and consequences remain aligned with the clinical and operational problem being addressed.

Clinical target product profile and use scenario

A clinical target product profile should define the characteristics required for a medicine to fulfil a specific therapeutic and care-delivery role. For long-acting products, it must extend beyond indication, strength, route, and dosing interval to specify intended users, administrators, care setting, follow-up requirements, missed-dose management, and product experiences that may influence uptake or persistence. Patient input is most valuable when incorporated prospectively and linked directly to development decisions rather than collected only as a retrospective measure of satisfaction [7].

The use scenario is proposed as a structured description of the complete pathway through which the product reaches and remains effective for the intended user. It includes initiation, procurement, storage, preparation, administration, monitoring, rescheduling, interruption, discontinuation, and re-entry into care. Disease-specific target product profiles for long-acting chemoprevention show that duration must be considered alongside population, safety, formulation, operational adherence, cost, access, and delivery setting [8]. The use scenario therefore gives context to attributes such as dosing interval, presentation, injection volume, storage conditions, and permissible pharmacokinetic tail.

A useful profile should distinguish minimum attributes required for product viability from preferred attributes that add value but permit transparent trade-offs. Multi-stakeholder target product profile development shows how desired characteristics can be defined and revised as scientific and contextual knowledge evolves [9]. Relevant stakeholders may include patients, caregivers, clinicians, nurses, pharmacists, scientists, manufacturers, procurement teams, and implementation specialists. Their roles are complementary rather than interchangeable, and consensus alone does not establish feasibility or clinical benefit.

The framework therefore organizes six upstream constructs: clinical need, therapeutic role, target population, use scenario, dosing-experience envelope, and implementation envelope. These shape the clinical target product profile and its exposure and performance requirements, which are then translated into pharmaceutical attributes. The process is iterative: if the dose is unacceptable, terminal exposure is unmanageable, the formulation is unstable, or the service pathway cannot sustain administration, the target profile should be revised rather than optimizing an internally inconsistent concept. This proposed architecture extends patient-centric target product thinking but does not define universal attribute values or decision weights.

Reverse-translation design framework

The proposed Clinical-Backcast Long-Acting Medicine Design Framework reverses a common platform-first sequence. Instead of selecting a depot technology and asking which duration it can produce, the framework begins by specifying the clinical problem, intended use, required exposure, acceptable dosing experience, and implementation pathway. Delivery technology is selected only after these requirements have been translated into dose, route, loading, release, stability, and process constraints. This order is particularly important for PLGA-based injectables because performance depends on interactions among the drug, polymer, formulation composition, manufacturing history, and biological environment rather than on polymer selection alone [10]. **Figure 1** presents the original conceptual synthesis for reverse-design pathway from clinical need to formulation attributes, showing how the article's principal components, evidence relationships, uncertainties, and decision boundaries are connected.



Figure 1. Reverse-Design Pathway from Clinical Need to Formulation Attributes.

This original conceptual synthesis shows proposed or evidence-supported relationships rather than measured effects. It is not a validated model, clinical recommendation, regulatory standard, or deployment-ready system.

The pathway first converts the clinical target product profile into a requirement envelope covering onset, duration, variability, missed-dose management, residual exposure, dose, route, administration burden, storage, and use-setting constraints. Each attribute requires both clinical justification and a defined evaluation method.

Next, drug properties, excipients, depot architecture, and biological conditions are integrated into a mechanistic hypothesis for release, degradation, absorption, and stability. Mechanism-informed development can guide material selection, process variables, and controls, although findings may not transfer across products or platforms [11].

The formulation is then linked to manufacturing because particle formation, drying, sterilization, filling, and packaging can alter microstructure and release [12]. Composition, quality attributes, and process parameters must therefore be evaluated together.

Feedback loops connect failures in exposure, administration, stability, manufacturing, or implementation to redesign of the formulation, platform, process, or target profile. The framework distinguishes conceptual plausibility, experimental validation, translational validation, and decision readiness; evidence at one level does not establish the next.

Required exposure profile and pharmacodynamic duration

A long-acting product should be designed against a required exposure profile rather than a nominal interval alone. The proposed exposure-and-effect envelope includes onset, minimum effective exposure, maximum acceptable exposure, peak-to-trough behavior, duration of clinically useful action, variability among users, missed-dose tolerance, and the trajectory after discontinuation. These features must be specified separately because the formulation can prolong measurable drug concentrations beyond the period in which continued exposure remains therapeutically desirable. Tail-phase analysis of injectable cabotegravir demonstrates that prolonged post-injection exposure is a distinct pharmacokinetic and safety consideration rather than simply an extension of useful duration [13].

Population variability further limits the usefulness of a single target interval. Body size, sex, absorption characteristics, injection-related variables, physiological state, and other covariates may alter peak concentrations, trough concentrations, apparent half-life, or time within a therapeutic exposure range. Population pharmacokinetic

modelling of oral and injectable cabotegravir shows that between-person variability and identifiable covariates affect exposure after long-acting administration [14]. The relevant translational question is therefore not whether the average profile lasts for a specified period, but whether the distribution of profiles remains adequate and manageable for the intended population.

Real-world use can introduce differences that are incompletely represented in tightly controlled development studies. Administration timing, injection technique, body composition, concomitant treatment, incomplete records, and heterogeneous care pathways may alter observed pharmacokinetics or the interpretation of exposure. Real-world population pharmacokinetic evaluation of cabotegravir illustrates the importance of testing trial-derived expectations under routine treatment conditions [15]. The framework consequently requires explicit assumptions about population diversity, late administration, interruption, bridging, re-initiation, and monitoring rather than treating the labelled interval as an invariant pharmaceutical property.

Pharmacodynamic duration must also be distinguished from pharmacokinetic persistence. A therapeutic effect may outlast measurable systemic exposure, or measurable exposure may persist after adequate target engagement has ended. The required interval should therefore be justified through an exposure–response or effect-based rationale appropriate to the molecule and indication. Where such a relationship remains uncertain, the uncertainty should be represented rather than hidden inside a duration target. The proposed exposure-and-effect envelope organizes these questions but does not provide universal concentration thresholds, exposure–response functions, or missed-dose rules.

Table 1 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for definitions, components, relationships, and intended uses in designing long-acting medicines backward from the clinical target product profile.

Table 1 summarizes the core components, evidence needs, and boundaries for designing long-acting medicines backward from the clinical target product profile.

Table 1. Core components and evidence requirements for designing long-acting medicines backward from the clinical target product profile

Component	Core function or relationship	Evidence required	Main failure or boundary
Clinical need and therapeutic role	Define the unresolved clinical problem before selecting a technology or platform [1].	Clinical rationale, comparator analysis, treatment goals, and stakeholder input.	Clinical need alone does not establish that a long-acting product is preferable.
Clinical target product profile	Translate clinical, patient, pharmaceutical, manufacturing, and implementation needs into justified minimum and preferred attributes [7].	Explicit attribute definitions, rationales, review, and revision rules.	Agreement on a profile does not establish feasibility or benefit.
Use scenario	Specify who uses the product, where, how, and under what preparation, monitoring, storage, interruption, and discontinuation conditions [8].	Workflow mapping, user research, and implementation evidence.	The assumed setting may be unrealistic or exclude intended users.
Dosing-experience envelope	Define acceptable limits for route, volume, pain, time, travel, privacy, and provider burden.	Human-factors studies, observed use, preference research, and patient-reported outcomes.	Stated preference may not predict initiation or persistence.
Exposure-and-effect envelope	Convert the intended interval into requirements for onset, exposure, effect duration, variability, missed doses, and terminal persistence [13, 14].	PK, PD, exposure–response, subgroup, interruption, and tail assessments.	Average exposure may conceal individual under- or overexposure.
Dose–platform feasibility	Assess dose, loading, volume, route, and release platform as a coupled system [10].	Formulation screening, loading, injectability or implantability testing, and dose justification.	Depot formation does not establish acceptable administration or bioavailability.
Compatibility and stability	Control degradation, interaction, and physical change during manufacture, storage, and residence in the body [11].	Compatibility, forced-degradation, stability, impurity, and mechanistic analytical studies.	Evidence from one formulation cannot be assumed transferable.

Process and quality architecture	Link material and process variables to structure, stability, and release performance [12].	Process-understanding, robustness, scale-up, and discriminatory analytical studies.	Producing a batch does not establish manufacturability or reproducibility.
Implementation envelope	Treat staffing, scheduling, procurement, reimbursement, storage, tracking, and resupply as product-design constraints.	Workflow testing, implementation research, equity assessment, and supply analysis.	Clinical effectiveness does not establish accessibility or operational readiness.
Validation and decision use	Match each claim and decision to evidence appropriate for its context of use.	Prospective testing, uncertainty analysis, multidisciplinary review, and defined decision criteria.	Passing one evidence layer does not establish clinical, regulatory, or implementation readiness.

Delivery platform, release mechanism, and dose burden

Platform selection should follow the required dose and exposure profile rather than precede them. A molecule requiring a large total dose may exceed the loading capacity of a tolerable injectable volume or acceptable implant size, whereas a highly potent molecule may permit several platform options. Experimental development of long-acting buprenorphine PLGA microparticles illustrates how drug characteristics, polymer design, particle properties, and release objectives jointly constrain formulation feasibility [16]. A desired interval is therefore not an independent specification: it is coupled to potency, dose mass, route, loading efficiency, administration frequency, and the acceptable dimensions of the dosage form.

Release mechanism provides the causal hypothesis connecting formulation structure to exposure. Diffusion, dissolution, osmotic transport, polymer erosion, swelling, precipitation, phase inversion, or degradation-mediated release may occur alone or in combination. Microsphere research demonstrates that microstructure develops during manufacture and evolves during hydration and degradation, influencing drug movement and release behavior [17]. Polymer identity or nominal composition is consequently an incomplete description of a long-acting product. Particle porosity, drug distribution, crystallinity, interfacial structure, residual solvent, molecular weight, and degradation environment may all affect the release profile.

Dose burden includes more than the mass of active ingredient. It encompasses the mass and volume of the complete formulation, number of injections or implants, device requirements, needle dimensions, preparation steps, administration time, and local tissue capacity. Increasing duration may require more drug, greater carrier mass, a more persistent matrix, or a slower-dissolving solid phase. Each strategy can create different constraints on injectability, depot tolerability, degradation, sterilization, and residual exposure. The framework therefore requires a dose–platform fit assessment before duration is treated as a feasible product target.

Analytical testing must distinguish among products or process conditions that are expected to differ meaningfully. Development of in-vitro release methods for long-acting injectable suspensions shows that method conditions must be selected to generate discriminatory and interpretable release behavior [18]. An accelerated test may be valuable for development or quality control, but rapid release under artificial conditions does not automatically predict in-vivo exposure. Release testing should therefore be classified by intended use: formulation screening, stability indication, batch discrimination, mechanistic investigation, comparability, or prediction. Claims of biological predictivity require separate evidence.

Administration experience, reversibility, and manageability

Administration experience begins before the formulation enters the body. Preparation, device assembly, resuspension, injection force, procedure duration, number of administrations, and required expertise influence both provider workload and patient experience. Pain after subcutaneous injection is affected by volume, rate, formulation properties, needle characteristics, site, temperature, and technique [19]. These relationships indicate that route alone cannot define administration burden. A product described as a single injection may still be difficult to prepare, painful to deliver, prolonged to administer, or unsuitable for a particular setting.

Acceptability is similarly multidimensional and conditional. Participants evaluating long-acting injectable HIV prevention weighed convenience and discretion against injection-related concerns, uncertainty, and contextual factors [20]. Such findings support prospective investigation of administration experience but do not establish universal acceptance. Acceptability before exposure may differ from acceptability after repeated administration,

and both may differ from persistence when users face travel, cost, waiting time, adverse effects, or changing treatment priorities.

Patient-reported outcomes from long-acting HIV treatment trials show that satisfaction and preference can improve when individuals experience reduced dosing frequency and perceive the regimen as convenient [21]. These outcomes are relevant product evidence, but they address only part of product fitness. Preference cannot substitute for adequate exposure, manageable toxicity, reliable manufacturing, or equitable access. The proposed framework therefore positions patient-reported experience beside, rather than above, pharmacological, safety, and implementation evidence.

The framework also distinguishes physical reversibility from clinical manageability. A removable implant may permit physical retrieval, although removal can itself be difficult or incomplete. An injectable depot is generally not recoverable after administration. Clinical manageability may instead include monitoring, rescue therapy, supplemental dosing, temporary bridging, management of adverse effects, or predefined follow-up during a prolonged tail. A product should not be labelled reversible merely because its effects can sometimes be treated. The appropriate requirement is an evidence-based account of what can be stopped, removed, counteracted, monitored, or allowed to resolve after administration.

Table 2 summarizes the evidence requirements and validation criteria for designing long-acting medicines backward from the clinical target product profile.

Table 2. Testable propositions and validation criteria for designing long-acting medicines backward from the clinical target product profile

Architecture layer	Core requirement	Validation criterion	Main failure or boundary
Clinical-need definition	Define the unresolved therapeutic and care-delivery problem.	The comparator, target population, and intended product role are explicit.	Clinical need alone does not establish that a long-acting product is appropriate.
Patient-informed target product profile	Translate patient, provider, and system needs into minimum and preferred attributes.	Attributes have clear rationales, evidence sources, and revision rules; patient input is prospective [7].	Stakeholder agreement does not establish feasibility or benefit.
Exposure-and-effect envelope	Define required onset, duration, variability, residual exposure, and missed-dose consequences.	Effective exposure and terminal persistence are characterized for the intended population [13].	Average exposure may conceal subgroup under- or overexposure.
Dose–platform fit	Match dose, route, volume, device, and platform to the required duration.	The required dose and release profile are achievable within acceptable administration constraints.	Duration may require excessive volume, carrier mass, or complexity.
Release-mechanism hypothesis	Explain how composition and microstructure generate release and exposure.	Mechanism-relevant material changes produce reproducible release changes [17].	Mechanistic plausibility does not establish in-vivo predictivity.
Compatibility and stability	Preserve chemical, physical, and functional performance through shelf life and use.	Relevant changes are detected and linked to release, safety, or product performance.	Stability under one condition does not support untested conditions.
Administration experience	Ensure preparation and administration are acceptable and reproducible.	Intended users perform administration reliably under representative conditions [19].	Preference or simulated use does not establish sustained real-world use.
Reversibility and manageability	Define responses to toxicity, discontinuation, or treatment change.	Product-specific removal, rescue, monitoring, or bridging plans are established.	Manageability does not imply physical reversibility.
Implementation and adherence	Confirm that services can deliver scheduled doses and manage interruptions.	Administration, access, supply, and missed-dose pathways are feasible in representative settings.	Product acceptability does not establish organizational readiness.
Evidence-integration gate	Judge whether evidence supports a specific development decision.	Claims are matched to context-appropriate evidence, with uncertainty stated.	Passing a framework gate is not regulatory approval or clinical recommendation.

Adherence, persistence, and health-system implementation

Long-acting dosage forms replace daily dosing with appointment-, access-, and system-dependent adherence. Digital tools alone may not improve administration-window adherence [22], while staffing, reimbursement, procurement, workflow, infrastructure, and access barriers can limit implementation despite high acceptability [23, 24]. Evaluation should therefore distinguish adherence, persistence, retention, and implementation and assess missed visits, discontinuation, re-initiation, and unequal access.

Manufacturing, storage, and supply constraints

Long-acting products are sensitive to material attributes, manufacturing history, platform type, and storage conditions. PLGA microsphere performance can vary with raw materials and processing [25], while different platforms require distinct production and control strategies [26]. Manufacturing may also affect suspension stability and efficiency [27]. Development should therefore define critical process, stability, transport, inventory, and supply assumptions early, without assuming that any manufacturing approach guarantees reliable supply..

Table 3 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for failure modes, boundary conditions, governance needs, and implementation priorities for designing long-acting medicines backward from the clinical target product profile.

Table 3. Failure modes, boundary conditions, governance needs, and implementation priorities for Designing Long-Acting Medicines Backward from the Clinical Target Product Profile.

Decision scenario	Evidence required	Corrective action	Decision boundary
Extend the dosing interval	Product-specific PK, PD, safety, variability, and missed-dose evidence support the proposed interval.	Shorten the interval, modify release or dose, or strengthen monitoring.	Detectable exposure does not establish prolonged therapeutic benefit.
Increase drug loading	Loading remains compatible with stability, release, volume, viscosity, and administration constraints.	Reformulate, divide the dose, change platform, or revise the target interval.	High loading does not establish bioavailability or tolerability.
Accept a prolonged terminal tail	Residual exposure, variability, and clinical consequences are characterized and manageable [13].	Add monitoring, bridging, rescue, follow-up, removal where possible, or redesign.	Persistence after treatment cannot be assumed beneficial.
Retain burdensome administration	Repeated-use and human-factors evidence shows acceptable pain, procedure time, volume, and provider burden.	Modify formulation, device, route, technique, interval, or setting.	Average preference does not establish acceptability for all users.
Rely on digital adherence support	Representative use shows that the tool improves the intended adherence process [22].	Add human support, redesign workflow or reminders, or revise scheduling.	Tool availability alone does not establish improved adherence or persistence.
Adopt complex manufacturing	Critical material and process variables are controlled across relevant scales.	Simplify, add controls, change platform, redesign, or stop development.	Pilot production does not establish commercial robustness.
Claim product similarity	Similarity is shown for attributes relevant to release and in-vivo performance [25].	Expand characterization, improve discriminatory testing, or obtain in-vivo evidence.	Nominal composition does not establish bioequivalence or clinical equivalence.
Use accelerated release testing	The method is discriminatory and qualified against real-time or in-vivo behavior.	Restrict its use, redevelop the method, or obtain bridging evidence.	Rapid in-vitro release does not establish human exposure.
Deploy in constrained settings	Staffing, supply, storage, access, monitoring, and recovery pathways are feasible in representative settings.	Adapt presentation or workflow, decentralize care, add support, or revise the target population.	Trial efficacy does not establish equitable implementation.
Progress despite uncertainty	Remaining uncertainty is bounded, non-critical, and addressed by a predefined evidence plan.	Continue conditionally, obtain further evidence, redesign, or terminate.	Conceptual plausibility does not establish readiness for consequential use.

Validation and decision gates

Validation should be claim- and use-specific. In-vitro reproducibility or in-vitro–in-vivo correlation does not establish predictive value across products, populations, or use conditions. For PLGA long-acting injectables, correlation strength depends on release behavior, study design, data quality, and modelling assumptions [28]. Integrated formulation, release, pharmacokinetic, and simulation evidence must therefore be assessed against the intended decision; a model suitable for formulation ranking may not support dosing, safety, comparability, or implementation decisions [29].

The framework proposes four gates: conceptual coherence; mechanistic and experimental confirmation; translation to in-vivo and human-use performance; and adequacy for the intended decision. Failure may require redesign rather than further testing. Some deficiencies are non-compensable: convenience cannot offset unacceptable persistence, preference cannot offset inadequate exposure, and technical performance cannot offset unmanageable risk or limited implementation capacity. These are proposed principles rather than validated regulatory or clinical thresholds.

Limitations and development priorities

Long-acting technologies vary substantially in formulation, manufacturing, release testing, and equivalence challenges [30]. The framework may therefore require adaptation for microspheres, suspensions, implants, in-situ depots, prodrugs, and biologically persistent products. It supports structured comparison but cannot predict development success or replace product-specific safety, stability, pharmacology, device, manufacturing, and implementation studies. Technical innovation alone does not ensure clinical translation [31].

Duration, burden, safety, reversibility, cost, manufacturability, and acceptability may conflict and cannot always be combined into one score. Non-compensable gates prevent critical failures from being obscured by aggregate assessments, although their boundaries remain context-dependent. **Figure 2** summarizes the proposed trade-offs, evidence relationships, uncertainties, and decision boundaries.



Figure 2. Long-Acting Product Trade-Offs across Duration, Burden, Safety, and Implementation.

The figure is an original conceptual synthesis developed for "Designing Long-Acting Medicines Backward from the Clinical Target Product Profile, Dosing Experience, Real-World Adherence, and Implementation Constraints." Arrows and grouping indicate proposed or evidence-supported relationships rather than measured effect sizes. The figure does not represent a validated predictive model, clinical recommendation, regulatory determination, or deployment-ready system.

Development priorities follow directly from these limitations. The framework should be evaluated prospectively in contrasting product classes and care settings, with predefined records of how upstream requirements generate downstream attributes and how evidence changes decisions. Stakeholder studies should test whether the construct definitions are understandable and whether important patient, provider, manufacturing, or implementation concerns are omitted. Comparative case studies should examine whether framework-guided programmes identify dose, tail, administration, stability, scale-up, or workflow failures earlier than conventional technology-first development. Such work would assess usefulness and transferability without assuming that the framework itself improves clinical outcomes.

CONCLUSION

Designing a successful long-acting medicine requires more than extending release or increasing the time between scheduled doses. The proposed Clinical-Backcast Long-Acting Medicine Design Framework begins with the clinical target product profile, intended use scenario, dosing experience, exposure-and-effect envelope, and implementation pathway, then translates these requirements into dose, platform, release, formulation, process, stability, storage, and supply attributes. It makes duration conditional on exposure adequacy, acceptable burden, safety manageability, patient and provider experience, manufacturing reliability, and health-system feasibility. Bidirectional traceability and proposed decision gates are intended to expose conflicts before local technical optimization is mistaken for whole-product success. The framework remains an original conceptual synthesis rather than a validated predictive model, clinical recommendation, regulatory standard, or universally applicable development method. Its value must be tested through product-specific experimental, manufacturing, pharmacological, human-factors, clinical, and implementation evidence.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Stegemann S, Sheehan L, Rossi A, Barrett A, Paudel A, Crean A, et al. Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes—a proposed roadmap. Eur J Pharm Biopharm. 2022;177:81-8. doi:10.1016/j.ejpb.2022.06.006
2. Shi Y, Lu A, Wang X, Belhadj Z, Wang J, Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B. 2021;11(8):2396-415. doi:10.1016/j.apsb.2021.05.002
3. Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57(1):106220. doi:10.1016/j.ijantimicag.2020.106220
4. Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018;13(1). doi:10.1371/journal.pone.0190487
5. Graham SM, Barthold D, Hauber B, Brah AT, Saldarriaga EM, Collier AC, et al. U.S. patient preferences for long-acting HIV treatment: A discrete choice experiment. J Int AIDS Soc. 2023;26(Suppl 2). doi:10.1002/jia2.26099
6. Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4). doi:10.1016/S2352-3018(20)30340-4
7. Talabardon JN, Church JE, Okuse M, Dinboeck M, Dickinson S, Messner S, et al. Incorporating patient input into the target product profile. Ther Innov Regul Sci. 2025;59(4):659-67. doi:10.1007/s43441-025-00783-1

8. El Gaaloul M, Tchouatieu AM, Kayentao K, Campo B, Buffet B, Ramachandruni H, et al. Chemoprevention of malaria with long-acting oral and injectable drugs: An updated target product profile. Malar J. 2024;23(1):315. doi:10.1186/s12936-024-05128-1
9. Lewin SR, Attoye T, Bansbach C, Doehle B, Dubé K, Dybul M, et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV. 2021;8(1). doi:10.1016/S2352-3018(20)30234-4
10. Park K. PLGA-based long-acting injectable formulations. J Control Release. 2025;382:113758. doi:10.1016/j.jconrel.2025.113758
11. Xiong Y, Wang J, Zhou X, Li X. The development of a stable peptide-loaded long-acting injection formulation through a comprehensive understanding of peptide degradation mechanisms: A QbD-based approach. Pharmaceutics. 2024;16(2):266. doi:10.3390/pharmaceutics16020266
12. Zhang C, Zhang R, Liu L, Yang M. Designing long-acting injectable formulations using PLGA via spray-drying. Int J Pharm. 2025;683:126083. doi:10.1016/j.ijpharm.2025.126083
13. Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: A secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7). doi:10.1016/S2352-3018(20)30106-5
14. Han K, Baker M, Lovern M, Paul P, Xiong Y, Patel P, et al. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. Br J Clin Pharmacol. 2022;88(10):4607-22. doi:10.1111/bcp.15439
15. Thoueille P, Alves Saldanha S, Schaller F, Choong E, Veuve F, Munting A, et al. Population pharmacokinetics of cabotegravir following oral administration and long-acting intramuscular injection in real-world people with HIV. Clin Pharmacol Ther. 2024;115(6):1450-9. doi:10.1002/cpt.3240
16. Otte A, Johnson C, Garner J, Park K. Long-acting injectable buprenorphine PLGA microparticle formulation. Int J Pharm. 2025;683:126006. doi:10.1016/j.ijpharm.2025.126006
17. Wang M, Wang S, Zhang C, Ma M, Yan B, Hu X, et al. Microstructure formation and characterization of long-acting injectable microspheres: The gateway to fully controlled drug release pattern. Int J Nanomedicine. 2024;19:1571-95. doi:10.2147/IJN.S445269
18. Bao Q, Wang X, Zou Y, Wang Y, Burgess DJ. In vitro release testing method development for long-acting injectable suspensions. Int J Pharm. 2022;622:121840. doi:10.1016/j.ijpharm.2022.121840
19. Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-96. doi:10.1007/s12325-019-01101-6
20. Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: Findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. 2019;22(10). doi:10.1002/jia2.25408
21. Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24(12):3533-44. doi:10.1007/s10461-020-02929-8
22. Wohlfeiler MB, Brunet L, Cochran Q, Fusco JS, Hsu RK, Fusco GP. Improving adherence to the target window for cabotegravir plus rilpivirine long-acting injections through the CHORUS app and web portal: A cluster randomized trial. J Int Assoc Provid AIDS Care. 2024;23:23259582241245223. doi:10.1177/23259582241245223
23. Hack J, Tarfa A, Sayles H, Fadul N. High acceptability but persistent barriers to implementation of long-acting injectable antiretrovirals: A nationwide cross-sectional survey of Ryan White clinics in the United States. Open Forum Infect Dis. 2025;12(4). doi:10.1093/ofid/ofaf192
24. Nguyen N, Lane B, Golub SA, Chastain C, Zucker J, King K, et al. Long-acting injectable ART to advance health equity: A descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project. J Int AIDS Soc. 2024;27(Suppl 1). doi:10.1002/jia2.26282
25. Zhou J, Walker J, Ackermann R, Olsen K, Hong JKY, Wang Y, et al. Effect of manufacturing variables and raw materials on the composition-equivalent PLGA microspheres for 1-month controlled release of leuprolide. Mol Pharm. 2020;17(5):1502-15. doi:10.1021/acs.molpharmaceut.9b01188
26. Thapa Magar K, Boucetta H, Zhao Z, Xu Y, Liu Z, He W. Injectable long-acting formulations and manufacturing techniques. Expert Opin Drug Deliv. 2024;21(6):881-904. doi:10.1080/17425247.2024.2374807

27. Pietrzak T, Szendzielorz Z, Borychowska J, Ratajczak T, Kubisiak M. The impact of a manufacturing process on the stability of microcrystalline long-acting injections: A case study on aripiprazole monohydrate. Pharmaceutics. 2025;17(6):735. doi:10.3390/pharmaceutics17060735
28. Wang Y, Otte A, Park H, Park K. In vitro-in vivo correlation development for long-acting injectable products based on poly(lactic-co-glycolic acid). J Control Release. 2025;377:186-96. doi:10.1016/j.jconrel.2024.11.021
29. Gong Y, Zhang P, Yoon M, Zhu H, Kohojkar A, Hooker AC, et al. Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products. CPT Pharmacometrics Syst Pharmacol. 2023;12(5):624-30. doi:10.1002/psp4.12931
30. O'Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144-58. doi:10.1016/j.jconrel.2021.06.017
31. Balash M, Boucetta H, He W. Factors affecting drug delivery system translation: A focus on advanced technologies, biological barriers, and regulatory challenges. J Control Release. 2025;387:114167. doi:10.1016/j.jconrel.2025.114167